Koers BioNTech SE Xetra
Aandelen
US09075V1026
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 2,75 mld. 2,94 mld. | Omzet 2025 * | 2,74 mld. 2,93 mld. | Marktkapitalisatie | 18,6 mld. 19,91 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -419 mln. -449 mln. | Nettowinst (verlies) 2025 * | -548 mln. -587 mln. | EV/omzet 2024 * | 2,16 x |
Nettoliquiditeiten 2024 * | 12,67 mld. 13,57 mld. | Nettoliquiditeiten 2025 * | 12,02 mld. 12,87 mld. | EV/omzet 2025 * | 2,4 x |
K/w-verhouding 2024 * |
-41,5
x | K/w-verhouding 2025 * |
-32,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,48% |
Recentste transcriptie over BioNTech SE
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ugur Sahin
CEO | Chief Executive Officer | 58 | 02-06-08 |
Özlem Türeci
FOU | Founder | 57 | 02-06-08 |
Jens Holstein
DFI | Director of Finance/CFO | 60 | 01-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rudolf Staudigl
BRD | Director/Board Member | 70 | 01-01-22 |
Director/Board Member | 67 | 02-06-08 | |
Helmut Jeggle
CHM | Chairman | 53 | 02-06-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,13% | 122 mld. | |
+19,65% | 115 mld. | |
+21,22% | 26,64 mld. | |
-17,47% | 16,32 mld. | |
-45,95% | 15,52 mld. | |
-19,28% | 15,49 mld. | |
+63,81% | 14,83 mld. | |
+1,94% | 13,67 mld. | |
+116,04% | 11,12 mld. |